Clinical trials: Neoplasm Recurrence
Breast Cancer
Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003730
- Testing
- fluorouracil, vinorelbine tartrate
- Where
- 17 sites in Belgium, France and 2 more
- Volunteers
- 80 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Cervical Cancer
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087113
- Testing
- pemetrexed disodium
- Where
- 22 sites in United States
- Sponsor
- Gynecologic Oncology Group
Leukemia
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
The prognosis for children and adults with acute lymphoblastic leukemia (ALL) has improved significantly over the years. Nevertheless, patients who experience disease relapse or induction failure along with patients having…
- Trial name
- NCT00020670
- Testing
- CD 40
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed or Refractory Hodgkin Lymphoma
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
This is an open-label, phase I/II dose escalation and expansion trial. The primary objective of dose escalation phase I study is to evaluate the safety and feasibility of SHR1701 in patients with relapsed or refractory classical…
- Trial name
- NCT05896046
- Testing
- SHR2554+ SHR1701, SHR-1701
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
High Risk Neuroblastoma, Recurrent Neuroblastoma
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
This phase I trial is to find out the best dose, possible benefits and/or side effects of magrolimab in combination with dinutuximab in treating patients with neuroblastoma that has come back (relapsed) or does not respond to…
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma
- Trial name
- NCT04751383
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 11 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase I trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have residual, recurrent, or metastatic malignant melanoma or other advanced cancer that has not responded to…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003451
- Testing
- recombinant interferon alfa, recombinant interleukin-12
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
The purpose of this study is to learn why certain drugs stop working in patients.In lab studies, tumors become resistant in several ways. Specific molecules seem to change and this may be why therapy stops working.
- Trial name
- NCT00897702
- Testing
- Blood draw, immunoenzyme technique, biopsy
- Where
- 7 sites in United States
- Volunteers
- 269 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Intestinal Failure, Catheter-Related Bloodstream Infection (CRBSI) Nos
Catheter Salvage in Intestinal Failure Patients
This is an observational study evaluating a catheter salvage strategy in relation to catheter-related bloodstream infections in patients with chronic intestinal failure dependent on home parenteral support.
- Trial name
- NCT03222232
- Testing
- catheter salvage
- Where
- Denmark
- Volunteers
- 715 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lymphoma, T-Cell, Peripheral
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2.
- Trial name
- NCT03742921
- Testing
- Istodax
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Celgene
Leukemia
Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can find cancer cells and carry cancer-killing substances to them without harming normal cells. This may be effective treatment for leukemia.
- Trial name
- NCT00643240
- Testing
- yttrium Y 90 anti-CD19 monoclonal antibody BU12, 111In-BU-12
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Crohn's Disease, Pediatric Onset
Growth Relapse and Outcomes With Therapy 1
Pediatric Crohn's Disease is a life long disease , presenting early in life.As such , it is imperative to be able to evaluate the risk for more severe disease and poorer outcomes when making the decision which therapies to offer…
- Trial name
- GROWTH1 (NCT00711945)
- Where
- Israel
- Volunteers
- 348 people
- Sponsor
- European Society of Pediatric Gastroenterology, Hepatology and Nutrition
Glioblastoma
Abemaciclib + Pembrolizumab In Glioblastoma
This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
- Trial name
- NCT04118036
- Testing
- Pembrolizumab, Abemaciclib
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
The purposee of this study is to determine the safety and dosing of Fenretinide when given continuously for 5 days, every 3 weeks, in pediatric patients with recurrent and/or resistant acute lymphoblastic leukemia (ALL), acute…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- Trial name
- NCT01187810
- Testing
- Fenretinide, Cytarabine, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- South Plains Oncology Consortium
Breast Cancer
Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.
Expression of ER, PR and HER2/neu in initial and recurrent breast cancer and correlate the results to different clinical and pathological parameters as patient age,sex, tumor location, status of nodal involvement and…
- Trial name
- NCT07056205
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Endometrial Carcinoma, Endometrial Carcinoma Stage III
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
GYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma.
- Trial name
- GYNORYLAQ™ (NCT07316361)
- Testing
- • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
EGFR Mutation-positive Inoperable or Reccrent NSCLC
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice
- Trial name
- NCT04155541
- Testing
- dacomitinib hydrate
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Pilonidal Sinus
GLUtEus Maximus Fascia Plasty Flap for Pilonidal Sinus
Surgical treatment is still gold standard for pilonidal sinus disease. Several surgical techniques have been proposed to treat this disease in the last two decades.
- Trial name
- GLUE (NCT03914729)
- Testing
- Primary Closure, Gluteus Maximus Fascia Plasty Flap
- Where
- Russia
- Volunteers
- 84 people
- Sponsor
- Russian Society of Colorectal Surgeons
Acute Lymphocytic Leukemia
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
This is a phase I, open-label, single-arm study conducted in China to evaluate the safety, tolerability, PK, and determine the recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD) (if applicable) of JWCAR029 in…
- Trial name
- NCT05727683
- Testing
- CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
This phase I clinical trial is studying the side effects and best dose of IMC-A12 in treating young patients with relapsed or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumors.
- Trial name
- NCT00609141
- Testing
- cixutumumab, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.